Planet Labs Slides 12% as Morgan Stanley Cuts Target in Half

Planet Labs PBC enters the week having lost 12% in five sessions, down to $13.40, while a dramatic analyst reversal reshapes the near-term narrative around what was, until recently, a stock carrying significant Street optimism.

The most arresting development is Morgan Stanley's target cut, filed on October 19. Analyst Kristine Liwag slashed her price objective from $35 to $19 while keeping an Equal-Weight rating. That is a 46% reduction in the target from a bellwether firm, filed the same day the stock was already under pressure. Barclays added context two weeks earlier by initiating coverage at Equal-Weight with a $17 target, effectively arriving at the party with a cautious view from the outset. The mean consensus target is $30.27, though that figure is being dragged higher by older, more optimistic targets. Needham, which rates the stock Buy, cut from $53 to $40 in early September after the last earnings print. Wedbush retains an Outperform with a $50 target but has not moved that figure since July. The directional message from recent months is clear: bulls are trimming ambition without abandoning conviction, while new entrants are arriving with sober entry points.

The positioning backdrop does not point to a short-squeeze setup. Short interest is running at 11.8% of the free float, up 14% over the past month, a meaningful build that has accelerated as the stock has fallen. That said, the borrow market is relaxed. Availability is at 965%, meaning roughly nine-and-a-half shares remain available to borrow for every one already out on loan. The cost to borrow is just 0.46%, down 23% on the week. Shorts are building, but they are doing so cheaply and easily, with no sign of a squeeze developing in the lending market. Options lean in the same direction: the put/call ratio is at 0.28, just one standard deviation above its 20-day average, near the bottom of its 52-week range. Calls still dominate the book, which sits oddly against the mounting short position and the price action.

The bull and bear cases are well-defined. Bulls point to the 200-satellite fleet and its daily-global-imaging archive as a genuinely hard-to-replicate moat, to RPO up 57% year on year to $346 million, and to three nine-figure sovereign contracts across Sweden, Japan and Germany that provide multi-year revenue visibility. F2Q27 revenue hit $116.1 million with the company guiding to 42% year-on-year growth at the midpoint. Bears push back on the revenue quality: defense and satellite-services deals that may not recur at scale, a capex outlook raised to $100-$115 million for FY27, a $1.5 billion ATM program that caps the valuation ceiling, and a free cash flow picture that critics say has been flattered by upfront deal cash rather than structural improvement. The EV/EBITDA multiple at 106 times, compressing but still stretched, is hard to defend without a clear path to durable earnings. The company's EPS momentum factor score sits at 2 out of 100 over 30 days and 1 over 90 days, some of the weakest readings available.

Alphabet remains the largest institutional holder at 9.7% of shares, unchanged in recent filings. CEO William Marshall has filed a Schedule 13D/A, carrying activist status on the register. That filing dates to January 2026 and covered a 5.2% stake, as last disclosed. His institution-listed holding has since been reported at 3.4%, a reminder that the 13D/G register reflects event-driven disclosures around the 5% threshold and holders can fall below without filing again. Recent insider activity has been uniformly in one direction: net sales of $5.1 million over the past 90 days. Every transaction flagged in the recent filings is a sale, and every one of those sales was executed under a pre-arranged 10b5-1 plan, including a $565,000 sale by director Robinson Kristen on October 15 and a $944,000 sale by President and CFO Ashley Johnson on September 17. Pre-arranged sales carry far less informational weight than discretionary ones, but the absence of any open-market buying at these levels is notable.

The last earnings print is the clearest historical reference point for what to expect on December 10. Planet Labs fell 9.4% the day after its most recent results and was down 16.5% five sessions later. That print delivered numbers that beat headline estimates but still left the stock lower as the market focused on the capex step-up and cash flow composition. The next report arrives with the stock already down 18% from a month ago, short interest at a one-month high, and the two most recent analyst actions pointing toward the $17-$19 range. The gap between those new targets and the older, higher estimates across the Street, and whether any further revisions narrow it or widen it further, is the clearest signal to watch into December.